Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis

Challenges to curing primary brain tumours

(2019) Kenneth Aldape et al.   Nature Reviews Clinical Oncology

Progress Toward Long-Term Survivors of Glioblastoma

(2019) J. Nathan Cantrell et al.   MAYO CLINIC PROCEEDINGS

Ten-year survival in glioblastoma. A systematic review

(2018) Tomasz Tykocki et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Tumor treating fields: a new approach to glioblastoma therapy

(2018) Jonathan Rick et al.   JOURNAL OF NEURO-ONCOLOGY

Current state of immunotherapy for glioblastoma

(2018) Michael Lim et al.   Nature Reviews Clinical Oncology

Current Challenges and Opportunities in Treating Glioblastoma

(2018) Andrea Shergalis et al.   PHARMACOLOGICAL REVIEWS

Survival of Ventricular and Periventricular High-Grade Gliomas: A Surveillance, Epidemiology, and End Results Program–Based Study

(2018) Wuyang Yang et al.   World Neurosurgery

A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location

(2018) Peter Woo et al.   World Neurosurgery

Persistent Disparities in Survival for Patients with Glioblastoma

(2018) Mostafa Fatehi et al.   World Neurosurgery

Molecular Pathogenesis and Emerging Treatment for Glioblastoma

(2018) Alexander D. Ramos et al.   World Neurosurgery

Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance

(2018) Evan K. Noch et al.   World Neurosurgery

A Critical Overview of Targeted Therapies for Glioblastoma

(2018) Kewal K. Jain   Frontiers in Oncology

Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma—A phase II multicentric, randomised study

(2017) Renata Ursu et al.   EUROPEAN JOURNAL OF CANCER

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

(2017) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

(2017) Michael Weller et al.   LANCET ONCOLOGY

CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014

(2017) Quinn T Ostrom et al.   NEURO-ONCOLOGY

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

(2017) James R. Perry et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of Glioblastoma in Older Adults

(2017) Kelly Braun et al.   Current Oncology Reports

Survival Trends in Elderly Patients with Glioblastoma in the United States: a Population-based Study

(2016) BINAY KUMAR SHAH et al.   ANTICANCER RESEARCH

A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma

(2016) R. Rampling et al.   CLINICAL CANCER RESEARCH

Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial

(2016) Carmen Balana et al.   JOURNAL OF NEURO-ONCOLOGY

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma

(2015) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

(2015) J. Schuster et al.   NEURO-ONCOLOGY

Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study

(2014) Kenneth F. Hofland et al.   ACTA ONCOLOGICA

Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients

(2014) Yang Wang et al.   Asia-Pacific Journal of Clinical Oncology

Epidemiologic and Molecular Prognostic Review of Glioblastoma

(2014) J. P. Thakkar et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Impact of Inpatient Rehabilitation on Function and Survival of Newly Diagnosed Patients With Glioblastoma

(2014) Pamela S. Roberts et al.   PM&R

Emerging Therapies for Glioblastoma

(2014) Alissa A. Thomas et al.   JAMA Neurology

Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial

(2013) Maria Teresa Solomón et al.   BMC CANCER

A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regime

(2013) Mario Teo et al.   BRITISH JOURNAL OF NEUROSURGERY

Predictors of Long-Term Survival in Patients With Glioblastoma Multiforme: Advancements From the Last Quarter Century

(2013) Nauman S. Chaudhry et al.   CANCER INVESTIGATION

Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial

(2013) Manfred Westphal et al.   LANCET ONCOLOGY

Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial

(2012) Hilko Ardon et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

(2012) Roger Stupp et al.   EUROPEAN JOURNAL OF CANCER

The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma

(2011) J. J. Vredenburgh et al.   CLINICAL CANCER RESEARCH

A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma

(2011) Ashwatha Narayana et al.   JOURNAL OF NEUROSURGERY

Supratentorial Glioblastoma Multiforme: The Role of Surgical Resection Versus Biopsy Among Older Patients

(2010) Kaisorn L. Chaichana et al.   ANNALS OF SURGICAL ONCOLOGY

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection

(2010) Kaisorn L. Chaichana et al.   JOURNAL OF NEUROSURGERY

Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival

(2010) Kaisorn L. Chaichana et al.   JOURNAL OF NEUROSURGERY

Intralesional Lymphokine-activated Killer Cells as Adjuvant Therapy for Primary Glioblastoma

(2009) Robert Owen Dillman et al.   JOURNAL OF IMMUNOTHERAPY

A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme

(2009) Kaisorn Chaichana et al.   JOURNAL OF NEUROSURGERY

Relationship of glioblastoma multiforme to the lateral ventricles predicts survival following tumor resection

(2008) Kaisorn L. Chaichana et al.   JOURNAL OF NEURO-ONCOLOGY